专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明专利

CA2935870A1 METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS 未知
公开(公告)号：CA2935870A1
公开(公告)日：2008-10-16
申请号：CA2935870
申请日：2008-04-07
申请人： IMMUNOLIGHT LLC
发明人： BOURKE FREDERIC A
IPC分类号： A61K41/00 , A61P35/00
摘要： Methods for the treatment of a cell proliferation disorder in a subject, involving: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of effecting a predetermined cellular change when activated, either alone or in combination with at least one energy modulation agent; and (2) applying an initiation energy from an initiation energy source to the subject, wherein the applying activates the activatable agent in situ, thus causing the predetermined cellular change to occur, wherein the predetermined cellular change treats the cell proliferation disorder, preferably by causing an increase or decrease in rate of cell proliferation, and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an autovaccine effect in a subject using the method.

42. 发明专利

AU2018201384B2 METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS 未知
公开(公告)号：AU2018201384B2
公开(公告)日：2019-11-28
申请号：AU2018201384
申请日：2018-02-26
申请人： IMMUNOLIGHT LLC
发明人： BOURKE FREDERIC A
IPC分类号： C07D413/00 , A61K31/00
摘要： Methods for the treatment of a cell proliferation disorder in a subject, involving: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of effecting a predetermined cellular change when activated, either alone or in combination with at least one energy modulation agent; and (2) applying an initiation energy from an initiation energy source to the subject, wherein the applying activates the activatable agent in situ, thus causing the predetermined cellular change to occur, wherein the predetermined cellular change treats the cell proliferation disorder, preferably by causing an increase or decrease in rate of cell proliferation, and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an auto vaccine effect in a subject using the method.

43. 发明专利

CA2720513C NON-INVASIVE SYSTEMS AND METHODS FOR IN-SITU PHOTOBIOMODULATION 未知
公开(公告)号：CA2720513C
公开(公告)日：2018-09-25
申请号：CA2720513
申请日：2009-04-02
申请人： IMMUNOLIGHT LLC , UNIV DUKE
发明人： BOURKE FREDERIC A , VO DINH TUAN , WALDER HAROLD
IPC分类号： A61N5/06 , A61K41/00 , A61N5/10
摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

44. 发明专利

AU2017213801A1 Phosphor-containing drug activator, suspension thereof, system containing the suspension, and methods for use 未知
公开(公告)号：AU2017213801A1
公开(公告)日：2018-08-16
申请号：AU2017213801
申请日：2017-02-02
申请人： UNIV DUKE , IMMUNOLIGHT LLC
发明人： WALDER HAROLD , BOURKE JR FREDERIC A , FATHI ZAKARYAE , BEYER WAYNE , OLDHAM MARK , ADAMSON JUSTUS , NOLAN MICHAEL
IPC分类号： A61N5/10 , A61K41/00 , A61K49/04
摘要： A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+and (3Ca3 (PO4)2Ca(F, CI)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier. A system for treating a disease in a subject in need thereof includes a) the above-noted suspension, b) a photoactivatable drug containing 8-methoxypsoralen (8-MOP or UVADEX) untethered from the two or more phosphors, c) one or more devices which infuse the photoactivatable drug and the suspension including the pharmaceutically acceptable carrier into a diseased site in the subject, and d) an x-ray source which is controlled to deliver a dose of x-rays to the subject for production of the ultraviolet light.

45. 发明专利

CA3013335A1 PHOSPHOR-CONTAINING DRUG ACTIVATOR, SUSPENSION THEREOF, SYSTEM CONTAINING THE SUSPENSION, AND METHODS FOR USE 未知
公开(公告)号：CA3013335A1
公开(公告)日：2017-08-10
申请号：CA3013335
申请日：2017-02-02
申请人： IMMUNOLIGHT LLC , UNIV DUKE , NORTH CAROINA STATE UNIV
发明人： WALDER HAROLD , BOURKE FREDERIC A , FATHI ZAKARYAE , BEYER WAYNE , OLDHAM MARK , ADAMSON JUSTUS , NOLAN MICHAEL
IPC分类号： A61N5/10 , A61K41/00 , A61K49/04
摘要： A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+and (3Ca3 (PO4)2Ca(F, CI)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier. A system for treating a disease in a subject in need thereof includes a) the above-noted suspension, b) a photoactivatable drug containing 8-methoxypsoralen (8-MOP or UVADEX) untethered from the two or more phosphors, c) one or more devices which infuse the photoactivatable drug and the suspension including the pharmaceutically acceptable carrier into a diseased site in the subject, and d) an x-ray source which is controlled to deliver a dose of x-rays to the subject for production of the ultraviolet light.

46. 发明专利

CA2682686C METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS 未知
公开(公告)号：CA2682686C
公开(公告)日：2016-12-20
申请号：CA2682686
申请日：2008-04-07
申请人： IMMUNOLIGHT LLC
发明人： BOURKE FREDERIC A
IPC分类号： A61K41/00 , A61K31/37 , A61N5/00 , A61P35/00
摘要： Methods for the treatment of a cell proliferation disorder in a subject, involving: (1 ) administering to the subject at least one activatable pharmaceutical agent that is capable of effecting a predetermined cellular change when activated, either alone or in combination with at least one energy modulation agent; and (2) applying an initiation energy from an initiation energy source to the subject, wherein the applying activates the activatable agent in situ, thus causing the predetermined cellular change to occur, wherein the predetermined cellular change treats the cell proliferation disorder, preferably by causing an increase or decrease in rate of cell proliferation, and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an auto vaccine effect in a subject using the method.

47. 发明专利

SA113340787B1 طرق وأنظمة لعلاج اضطرابات تكاثر الخلايا 未知
公开(公告)号：SA113340787B1
公开(公告)日：2015-12-31
申请号：SA113340787
申请日：2008-04-07
申请人： IMMUNOLIGHT LLC
发明人： N/A
摘要： يتعلقالاختراعالحاليبطرقمعالجةاضطرابتكاثرخلايا treatment of a cell proliferation disorder فيأحدالأفراد،حيثتشتملعلى: (1) إعطاءالفردالمعالجعاملاًصيدلانياًواحداًعلىالأقلقابلاًللتفعيلقادراًعلىإحداثتغييرخلوي cellular change محددسلفاًعندتفعيله،إماوحدهأوفيتوليفةمععاملتعديلطاقة energy modulation agent واحدعلىالأقل؛و (2) إعطاءطاقةبدء initiation energy منمصدرطاقةبدءللفردالمعالج، حيثيؤديالإعطاءإلىتفعيلالعاملالقابلللتفعيلفيالموضع،لهذايتمإحداثالتغييرالخلويالمحددسلفاً predetermined cellular change ،حيثيعالجالتغييرالخلويالمحددسلفاً predetermined cellular change اضطرابتكاثرالخلايا cell proliferation disorder ،يفضلمنخلالإحداثزيادةأوانخفاضفيمعدلتكاثرالخلايا increase or decrease in rate of cell proliferation ،ومجموعةلتنفيذالطريقة،ونظاميتمتنفيذهبالكمبيوترلتنفيذالطريقة،وتركيبةصيدلانيةمفيدةفيالطريقةوطريقةلإحداثتأثيرلقاحذاتي autovaccine فيالفردالمعالجباستخدامالطريقة. شكل ( 1 ) .

48. 发明专利

IN3077DEN2015A “A KIT FOR PERFORMING A CELL PROLIFERATION DISORDER TREATMENT” 未知
公开(公告)号：IN3077DEN2015A
公开(公告)日：2015-10-02
申请号：IN3077DEN2015
申请日：2015-04-13
申请人： IMMUNOLIGHT LLC
发明人： FREDERIC A BOURKE
IPC分类号： A61K31/35
摘要： A kit for performing a cell proliferation disorder treatment, comprising: at least one activatable pharmaceutical agent capable of causing a predetermined cellular change; at least one energy modulation agent capable of activating the at least one activatable pharmaceutical agent when energized; and containers suitable for storing the agents in stable form.

49. 发明专利

AR071831A1 SISTEMAS NO INVASIVOS Y METODOS PARA FOTOBIOMODULACION IN SITU. COMPOSICION FARMACEUTICA. KIT. 未知
公开(公告)号：AR071831A1
公开(公告)日：2010-07-21
申请号：ARP090101189
申请日：2009-04-03
申请人： UNIV DUKE , IMMUNOLIGHT LLC
IPC分类号： A61K31/37 , A61K31/198 , A61K33/24 , A61K33/38 , A61K38/40 , A61K47/42 , A61K41/00 , A61P37/00 , A61B18/00 , A61M37/00
摘要： Productos, composiciones, sistemas y metodos para modificar una estructura blanco que media o est asociada con una actividad biologica, incluyendo tratamiento de afecciones, trastornos, o enfermedades mediadas por o asociadas con una estructura blanco, tal como un virus, una celula, estructura celular o estructura extracelular. Kits que contienen los productos o las composiciones formuladas o configuradas y sistemas para usar en la puesta en pr ctica de estos metodos. Reivindicacion 1: Una composicion farmaceutica para modificar una estructura pretendida que media o est asociada con una actividad biologica, que comprende: por lo menos un agente seleccionado del grupo que consiste en agentes de modulacion de energ¡a, agentes activosplasmonicos y combinaciones de los anteriores; y a veh¡culo aceptable desde el punto de vista farmaceutico. Reivindicacion 2: La composicion farmaceutica de la reivindicacion 1, comprende adem s una fuente de energ¡a qu¡mica. Reivindicacion 3: La composicion farmaceutica de la reivindicacion 2, en la cual la fuente de energ¡a qu¡mica es un elemento seleccionado del grupo que consiste en compuestos fluorescentes, compuestos quimioluminiscentes, compuestos bioluminiscentes y enzimas emisoras de luz. Reivindicacion 5: La composicion farmaceutica de la reivindicacion 1, que comprende adem s por lo menos un agente farmaceutico susceptible de activacion. Reivindicacion 9: La composicion farmaceutica de la reivindicacion 5, en la cual el por lo menos un agente farmaceutico susceptible de activacion es 8-MOP o AMT. Reivindicacion 10: La composicion farmaceutica de la reivindicacion 5, en la cual el por lo menos un agente farmaceutico susceptible de activacion es uno seleccionado de 7,8-dimetil-1 0-ribitilo, isoaloxazina, 7,8,10-trimetilisoaloxazina, 7,8-dimetilaloxazina, isoaloxazina-adenina dinucleotido, aloxazina mononucleotido, tetrasulfonato de aluminio (III) ftalocianina, hematoporfirina, y ftadocianina. Reivindicacion 12: La composicion farmaceutica de la reivindicacion 11, en la cual el veh¡culo es uno seleccionado de insulina, interleucina, timopoyetina o transferrina. Reivindicacion 31: La composicion farmaceutica de la reivindicacion 28, en la cual el agente activo-plasmonico es una sonda PEPST que comprende nano estructuras de metal activas con plasmonicos. Reivindicacion 61: La composicion farmaceutica de la reivindicacion 1, comprende adem s por lo menos un aditivo que tiene un efecto terapeutico o de diagnostico complementario, en la cual dicho aditivo es por lo menos un elemento seleccionado del grupo que consiste en antioxidantes, adyuvantes, fuentes de energ¡a qu¡micas, y combinaciones de los anteriores. Reivindicacion 105: Una composicion que comprende por lo menos un agente farmaceutico susceptible de activacion (PA) que es capaz de efectuar un cambio predeterminado en una estructura pretendida cuando se activa, y, en forma opcional, por lo menos un elemento seleccionado del grupo que consiste en agentes de modulacion de energ¡a, agentes activos-plasmonicos y combinaciones de los anteriores, para usar en la fabricacion de un medicamento para un tratamiento que modifica una estructura pretendida que media o est asociada con una actividad biologica, en el cual el tratamiento comprende: (1) contactar dicha estructura pretendida con la composicion farmaceutica; y (2) aplicar una energ¡a de iniciacion proveniente de una fuente de energ¡a de iniciacion a dicha estructura pretendida, donde el agente de modulacion de energ¡a, si est presente, eleva o disminuye la energ¡a de iniciacion a una energ¡a de activacion capaz de activar el por lo menos un agente farmaceutico susceptible de activacion; donde el agente activo-plasmonico, si est presente, potencia o modifica la energ¡a de iniciacion aplicada o la energ¡a de activacion generada por el agente de modulacion de energ¡a, o ambos; y de este modo logrando que ocurra el cambio predeterminado a la estructura pretendida, en el cual dicho cambio predeterminado modifica la estructura pretendida y modula la actividad biologica de la estructura pretendida.

50. 发明专利

CA3095369A1 NON-INVASIVE SYSTEMS AND METHODS FOR IN-SITU PHOTOBIOMODULATION 未知
公开(公告)号：CA3095369A1
公开(公告)日：2009-10-08
申请号：CA3095369
申请日：2009-04-02
申请人： IMMUNOLIGHT LLC , UNIV DUKE
发明人： BOURKE FREDERIC A , VO DINH TUAN , WALDER HAROLD
IPC分类号： A61K41/00 , A61K47/50 , A61K47/66
摘要： Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by application of an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式